Strides Pharma Global Pte. Limited, a step-down wholly-owned subsidiary of Strides Pharma, has received approval from the United States Food & Drug Administration (USFDA) for its generic version of Theophylline extended-release tablets, 300 mg and 450 mg. This approval marks a significant milestone for the company, strengthening its presence in the U.S. pharmaceutical market.
Theophylline extended-release tablets are indicated for the treatment of symptoms and reversible airflow obstruction associated with chronic asthma, emphysema, and chronic bronchitis. These conditions affect millions worldwide, causing symptoms such as wheezing, shortness of breath, and chest tightness. The drug functions as a bronchodilator, relaxing the muscles around the bronchial tubes to ease breathing.
Clinical Significance and Market Impact
The extended-release formulation of Theophylline allows for prolonged drug release, reducing the frequency of dosing and providing consistent relief from symptoms over time. This is particularly beneficial for patients requiring long-term management of chronic respiratory conditions. The combined market size for Theophylline Extended-Release Tablets, 300 mg and 450 mg, is $11.5 million, with the 300 mg dosage contributing $10.8 million, according to IQVIA data.
"This approval underscores our commitment to providing affordable and accessible medications for patients with chronic respiratory diseases," said a company spokesperson. "We are confident that our generic Theophylline tablets will offer a cost-effective alternative to the reference listed drug, Theo-Dur, while maintaining the same high standards of quality and efficacy."
Manufacturing and Distribution
The Theophylline tablets will be manufactured at Strides Pharma's flagship facility in KRS Gardens, Bangalore, India. This state-of-the-art facility ensures the production of high-quality pharmaceuticals, adhering to stringent regulatory standards. Strides Pharma is an integrated manufacturer and exporter of finished pharmaceutical dosage forms for both branded and generic markets.
Strides Pharma's Market Position
Headquartered in Bengaluru, India, Strides Pharma has a market capitalization of ₹12,586.32 crore. The company produces a broad range of ethical pharmaceuticals, over-the-counter (OTC) products, and nutraceuticals, catering to global demand. The recent USFDA approval is expected to further enhance the company's growth trajectory and market value.
